A Clinical Study to Evaluate the Pharmacokinetic and Pharmacodynamics Properties of of SHR-3167 Injection at Steady State in Subjects With Type 2 Diabetes
Latest Information Update: 07 Oct 2025
At a glance
- Drugs SHR-3167 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Jiangsu Hengrui Medicine Co.
Most Recent Events
- 10 Sep 2025 Status changed from not yet recruiting to recruiting.
- 30 Jun 2025 New trial record